Now showing items 1-2 of 2

    • 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study 

      de la Torre, Rafael; Martín-Santos, Rocío; Torrens, M.; Poudevida, Sandra; Langohr, Klaus; Cuyas, Elisabet; Pacifici, Roberta; Farré, Magí; Pichini, Simona (2010-01)
      Restricted access - publisher's policy
      A 3-year longitudinal prospective study was conducted to compare the incidence of substance use disorders (SUD) and non-substance use disorders (NSUD) among ecstasy users and two control groups: one of cannabis users and ...
    • Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy''): the influence of gender and genetics (CYP2D6, COMT, 5-HTT) 

      Pardo-Lozano, Ricardo; Farré, Magí; Yubero-Lahoz, Samanta; O’Mathúna, Brian; Torrens, M.; Mustata, Cristina; Pérez-Mañá, Clara; Langohr, Klaus; Cuyàs, Elisabet; Carbó, Marcel·lí; de la Torre, Rafael (2012-10-24)
      Open Access
      The synthetic psychostimulant MDMA (63,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6). ...